Interactions of iron oxide nanoparticles with the immune system: Challenges and opportunities for their use in nano-oncology

Current Pharmaceutical Design

Volumn 19, Issue 37, 2013, Pages 6606-6621

  Baiu, Dana C ^a   Brazel, Christopher S ^c   Bao, Yuping ^c   Otto, Mario ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c University of Alabama   (United States)

Author keywords

Cancer theranostics; Immunology; Inflammation; Iron oxide nanoparticles; Macrophage; Nanoparticle surface chemistry; Tumor targeting

Indexed keywords

ANTIBODY; C 184; CARBOXYMETHYLDEXTRAN; CHEMOKINE; CHITOSAN; CLIAVIST; CYTOKINE; DEXTRAN; FERROMAGNETIC MATERIAL; FERUCARBOTRAN; FERUGLOSE; FERUMOXSIL; FERUMOXYTOL; GLUCOSE POLYMER; IRON OXIDE NANOPARTICLE; MACROGOL; MAGNETITE; MICROMOD SPIO; NANOPARTICLE; NANOTHERM; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; REACTIVE OXYGEN METABOLITE; SILANE; SILOXANE; SORBITOL; STARCH; SUPERPARAMAGNETIC INVERSE SPINEL FERRITE NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRACER; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY SMALL OXIDE PARTICLE;

ABDOMINAL AORTA ANEURYSM; ADAPTIVE IMMUNITY; ANEMIA; ANTIBODY RESPONSE; ATHEROSCLEROTIC PLAQUE; ATOM TRANSFER RADICAL POLYMERIZATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CELLULAR IMMUNITY; CLICK CHEMISTRY; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG TARGETING; HEART INFARCTION; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LIVER CELL CARCINOMA; LIVER METASTASIS; LYMPH NODE METASTASIS; MACROPHAGE; MATERIAL COATING; MOLECULAR IMAGING; MOLECULAR INTERACTION; MULTIPLE SCLEROSIS; MYOCARDITIS; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SARCOMA; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; FERRIC COMPOUNDS; HUMANS; IMMUNE SYSTEM; NANOPARTICLES; NEOPLASMS;

EID: 84887893535     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990409     Document Type: Review

References (142)

1. Cancer NANOTECHNOLOGY: Going Small for Big Advances. Using Nanotechnology to Advance Cancer Diagnosis, Prevention and Treatment. [Bulletin on the Internet]. U. S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute. [updated 2004 January; cited 2013 February 10]. Available from: http://nano. cancer. gov/objects/pdfs/Cancer_brochuré091609-508. pdf.
2. Lu M, Cohen MH, Rieves D, et al. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010; 85: 315-319.
3. Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med 2012; 3: 77-85.
4. Mahmoudi M, Serpooshan V, Laurent S. Engineered nanoparticles for biomolecular imaging. Nanoscale 2011; 3: 3007-26.
5. Yang L, Mao H, Wang YA, et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 2009; 5: 235-43.
6. Lee JH, Huh YM, Jun YW, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 2007; 13: 95-9.
7. Branca RT, Cleveland ZI, Fubara B, et al. Molecular MRI for sensitive and specific detection of lung metastases. Proc Natl Acad Sci USA 2010; 107: 3693-7.
8. Koyama T, Shimura M, Minemoto Y, et al. Evaluation of selective tumor detection by clinical magnetic resonance imaging using antibody-conjugated superparamagnetic iron oxide. J Control Release 2012; 159: 413-8.
9. Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2011; 103: 317-24.
10. Johannsen M, Gneveckow U, Thiesen B, et al. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur Urol 2007; 52: 1653-61.
11. Karmali PP, Chao Y, Park JH, et al. Different effect of hydrogelation on antifouling and circulation properties of dextraniron oxide nanoparticles. Mol Pharm 2012; 9: 539-45.
12. Smith A. Neurodegenerative diseases: Ferritin out iron's role. Nat Rev Drug Discov 2003; 2: 338.
13. Hahn PF, Stark DD, Lewis JM, et al. First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. Radiology 1990; 175: 695-700.
14. Seneterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996; 200: 785-92.
15. Zhang Y, Dodd SJ, Hendrich KS, et al. Magnetic resonance imaging detection of rat renal transplant rejection by monitoring macrophage infiltration. Kidney Int 2000; 58: 1300-10.
16. Trivedi RA, JM UK-I, Graves MJ, et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 2004; 35: 1631-5.
17. ClinicalTrials. gov [homepage on the Internet]. A Service of the U. S. National Institutes of Health. [updated 2012 October 11; cited 2012 October 12]. Available from: http://clinicaltrials. gov/. In.
18. Johnson WK, Stoupis C, Torres GM, et al. Superparamagnetic iron oxide (SPIO) as an oral contrast agent in gastrointestinal (GI) magnetic resonance imaging (MRI): comparison with state-of-theart computed tomography (CT). Magn Reson Imaging 1996; 14: 43-9.
19. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 2003; 13: 1266-76.
20. Reimer P, Bremer C, Allkemper T, et al. Myocardial perfusion and MR angiography of chest with SH U 555 C: results of placebocontrolled clinical phase i study. Radiology 2004; 231: 474-81.
21. Tombach B, Reimer P, Bremer C, et al. First-pass and equilibrium-MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study. NMR Biomed 2004; 17: 500-6.
22. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003; 107: 2453-8.
23. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-9.
24. Christen T, Ni W, Qiu D, et al. High-resolution cerebral blood volume imaging in humans using the blood pool contrast agent ferumoxytol. Magn Reson Med 2012 in press.
25. Taupitz M, Wagner S, Schnorr J, et al. Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radiol 2004; 39: 394-405.
26. Kaufels N, Korn R, Wagner S, et al. Magnetic resonance imaging of liver metastases: experimental comparison of anionic and conventional superparamagnetic iron oxide particles with a hepatobiliary contrast medium during dynamic and uptake phases. Invest Radiol 2008; 43: 496-503.
27. Johannsen M, Gneveckow U, Taymoorian K, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia 2007; 23: 315-23.
28. Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995, 196: 481-8.
29. Bartolozzi C, Lencioni R, Donati F, et al. Abdominal MR: liver and pancreas. Eur Radiol 1999, 9: 1496-512.
30. Scott J, Ward J, Guthrie JA, Wilson D, Robinson PJ. MRI of liver: a comparison of CNR enhancement using high dose and low dose ferumoxide infusion in patients with colorectal liver metastases. Magn Reson Imaging 2000, 18: 297-303.
31. Zheng WW, Zhou KR, Chen ZW, Shen JZ, Chen CZ, Zhang SJ. Characterization of focal hepatic lesions with SPIO-enhanced MRI. World J Gastroenterol 2002, 8: 82-6.
32. Yoshikawa T, Mitchell DG, Hirota S, et al. Gradient-and spinecho T2-weighted imaging for SPIO-enhanced detection and characterization of focal liver lesions. J Magn Reson Imaging 2006; 23: 712-9.
33. Savranoglu P, Obuz F, Karasu S, et al. The role of SPIO-enhanced MRI in the detection of malignant liver lesions. Clin Imaging 2006; 30: 377-81.
34. Richards JM, Shaw CA, Lang NN, et al. In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans. Circ Cardiovasc Imaging 2012; 5: 509-17.
35. U. S. Food and Drug Administration [homepage on the Internet]. U. S. Department of Health and Human Services. [updated 2012 October 04; cited 2012 October 12]. Available from: http://www. fda. gov/.
36. Lee JY, Kim SH, Jeon YH, et al. Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience. J Comput Assist Tomogr 2010; 34: 127-34.
37. Choi JY, Kim MJ, Kim JH, et al. Detection of hepatic metastasis: manganese-and ferucarbotran-enhanced MR imaging. Eur J Radiol 2006; 60: 84-90.
38. Saito K, Shindo H, Ozuki T, et al. Perfusion study of hypervascular hepatocellular carcinoma with SPIO. Magn Reson Med Sci 2005; 4: 151-8.
39. Okada M IY, Kim T, Kogita S, et al. Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate-and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 2010; 32: 903-13.
40. Kawahara I, Nakamoto M, Hayashi K, et al. The detection of carotid plaque rupture caused by intraplaque hemorrhage by serial high-resolution magnetic resonance imaging: a case report. Surg Neurol 2008; 70: 634-9.
41. Yilmaz A, Rosch S, Klingel K, et al. Magnetic resonance imaging (MRI) of inflamed myocardium using iron oxide nanoparticles in patients with acute myocardial infarction-Preliminary results. Int J Cardiol 2013; 163: 175-82.
42. Toso C, Vallee JP, Morel P, et al. Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am J Transplant 2008; 8: 701-6.
43. Vellinga MM, Vrenken H, Hulst HE, et al. Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. J Magn Reson Imaging 2009; 29: 774-9.
44. Bunce NH, Keegan J, Gatehouse PD, et al. Initial experience with the intravascular contrast agent NC100150-injection (Clariscan) for breath-hold and navigator-gated magnetic resonance coronary artery imaging. J Magn Reson Imaging 2002; 16: 217-23.
45. Klein C, Schalla S, Schnackenburg B, et al. Improvement of image quality of non-invasive coronary artery imaging with magnetic resonance by the use of the intravascular contrast agent Clariscan (NC100150 injection) in patients with coronary artery disease. J Magn Reson Imaging 2003; 17: 656-62.
46. Leiner T, Ho KY, Ho VB, et al. Multicenter phase-II trial of safety and efficacy of NC100150 for steady-state contrast-enhanced peripheral magnetic resonance angiography. Eur Radiol 2003, 13: 1620-7.
47. Saokar A, Gee MS, Islam T, et al. Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10. Clin Imaging 2010; 34: 448-52.
48. Heesakkers RA, Jager GJ, Hovels AM, et al. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology 2009; 251: 408-14.
49. Meijer HJ, van Lin EN, Debats OA, et al. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2012; 82: 1405-10.
50. Ishigami K, Tajima T, Fujita N, et al. Hepatocellular carcinoma with marginal superparamagnetic iron oxide uptake on T2*-weighted magnetic resonance imaging: histopathologic correlation. Eur J Radiol 2011; 80: e293-8.
51. Richards JM, Semple SI, MacGillivray TJ, et al. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: a pilot study. Circ Cardiovasc Imaging 2011; 4: 274-281.
52. Tourdias T, Roggerone S, Filippi M, et al. Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium-and superparamagnetic iron oxide-enhanced MR imaging. Radiology 2012; 264: 225-33.
53. Fortuin AS, Deserno WM, Meijer HJ, et al. Value of PET/CT and MR Lymphography in Treatment of Prostate Cancer Patients With Lymph Node Metastases. Int J Radiat Oncol Biol Phys 2012; 84: 712-8.
54. Wagner M, Wagner S, Schnorr J, et al. Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: initial experience in humans. J Magn Reson Imaging 2011; 34: 816-23.
55. Li Calzi S, Kent DL, Chang KH, et al. Labeling of stem cells with monocrystalline iron oxide for tracking and localization by magnetic resonance imaging. Microvasc Res 2009; 78: 132-9.
56. Uchida M, Flenniken ML, Allen M, et al. Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J Am Chem Soc 2006; 128: 16626-33.
57. Kim DH, Zeng H, Ng TC, et al. T1 and T2 relaxivities of succimercoated MFe2 3+O4 (M=Mn2+, Fe2+ and Co2+) inverse spinel ferrites for potential use as phase-contrast agents in medical MRI. J Magn Magn Mater 2009; 321: 3899-904.
58. Palchoudhury S, An W, Xu Y, et al. Synthesis and growth mechanism of iron oxide nanowhiskers. Nano Lett 2011; 11: 1141-6.
59. Palchoudhury S, Xu Y, Goodwin J, et al. Synthesis of Iron Oxide Nanoworms. J Applied Physics 2011; 109.
60. Palchoudhury S, Xu Y, Rushdi A, et al. Controlled synthesis of iron oxide nanoplates and nanoflowers. Chem Commun (Camb) 2012; 48: 10499-501.
61. Duncan R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Technolo Today 1999, 2: 441-9.
62. Iyer AK, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11: 812-8.
63. Larsen EK, Nielsen T, Wittenborn T, et al. Size-Dependent Accumulation of PEGylated Silane-Coated Magnetic Iron Oxide Nanoparticles in Murine Tumors. ACS Nano 2009; 3: 1947-51.
64. Tal M, Wetzler M, Josefberg Z, et al. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res 1988, 48: 1517-20.
65. Awada A, Bozovic-Spasojevic I, Chow L. New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? Cancer Treat Rev 2012; 38: 494-504.
66. Katano M, Sidell N, Irie RF. Human monoclonal antibody to a neuroectodermal tumor antigen (OFA-I-2). Ann N Y Acad Sci 1983, 417: 427-34.
67. Mujoo K, Spiro RC, Reisfeld RA. Characterization of a unique glycoprotein antigen expressed on the surface of human neuroblastoma cells. J Biol Chem 1986, 261: 10299-305.
68. Otto M, Barfield R, Martin W, et al. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14. 18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin Cancer Res 2005; 11: 8486-91.
69. Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets 2010; 10: 200-9.
70. Moghimi SM, Hunter AC, Murray JC. Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev 2001, 53: 283-318.
71. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2012.
72. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR. Am J Roentgenol 1989, 152: 167-73.
73. Muller K, Skepper JN, Posfai M, et al. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro. Biomaterials 2007; 28: 1629-42.
74. Hsiao JK, Chu HH, Wang YH, et al. Macrophage physiological function after superparamagnetic iron oxide labeling. NMR Biomed 2008; 21: 820-9.
75. Lunov O, Syrovets T, Buchele B, et al. The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. Biomaterials 2010; 31: 5063-71.
76. Lunov O, Syrovets T, Rocker C, et al. Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials 2010; 31: 9015-22.
77. Gu J, Xu H, Han Y, et al. The internalization pathway, metabolic fate and biological effect of superparamagnetic iron oxide nanoparticles in the macrophage-like RAW264. 7 cell. Sci China Life Sci 2011; 54: 793-805.
78. Hoskins C, Cuschieri A, Wang L. The cytotoxicity of polycationic iron oxide nanoparticles: common endpoint assays and alternative approaches for improved understanding of cellular response mechanism. J Nanobiotechnol 2012; 10: 15.
79. Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J Clin Pathol 2011; 64: 281-6.
80. Evstatiev R, Gasche C. Iron sensing and signalling. Gut 2012; 61: 933-52.
81. Minotti G, Aust SD. The role of iron in the initiation of lipid peroxidation. Chem Phys Lipids 1987, 44: 191-208.
82. Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 2008; 4: 278-86.
83. Naqvi S, Samim M, Abdin M, et al. Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int J Nanomed 2010; 5: 983-9.
84. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12: 991-1045.
85. Rock KL, Latz E, Ontiveros F, et al. The sterile inflammatory response. Annu Rev Immunol 2010; 28: 321-42.
86. Mantovani A, Sica A, Allavena P, et al. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 2009; 70: 325-30.
87. Guildford AL, Poletti T, Osbourne LH, et al. Nanoparticles of a different source induce different patterns of activation in key biochemical and cellular components of the host response. J R Soc Interface 2009; 6: 1213-21.
88. Janic B, Iskander AS, Rad AM, et al. Effects of ferumoxidesprotamine sulfate labeling on immunomodulatory characteristics of macrophage-like THP-1 cells. PLoS One 2008; 3: e2499.
89. Siglienti I, Bendszus M, Kleinschnitz C, et al. Cytokine profile of iron-laden macrophages: implications for cellular magnetic resonance imaging. J Neuroimmunol 2006; 173: 166-73.
90. Fazilleau N, Mark L, McHeyzer-Williams LJ, et al. Follicular helper T cells: lineage and location. Immunity 2009; 30: 324-35.
91. Shen CC LH, Wang CC, Liao MH, et al. A role of cellular glutathione in the differential effects of iron oxide nanoparticles on antigen-specific T cell cytokine expression. Int J Nanomedicine 2011; 6: 2791-8.
92. Shen CC LH, Wang CC, Liao MH, et al. Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity. Int J Nanomedicine 2012; 7: 2729-37.
93. Shen CC, Wang CC, Liao MH, et al. A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice. Int J Nanomedicine 2011; 6: 1229-35.
94. Bailie GR, Clark JA, Lane CE, et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443-9.
95. Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-82.
96. Coppol E, Shelly J, Cheng S, et al. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population (February). Ann Pharmacother 2011 in press.
97. Chacko BK, Appukuttan PS. Dextran-binding human plasma antibody recognizes bacterial and yeast antigens and is inhibited by glucose concentrations reached in diabetic sera. Mol Immunol 2003, 39: 933-9.
98. Paul A, Geetha M, Chacko BK, et al. Multiple specificity of human serum dextran-binding immunoglobulin: alpha (1-->6)-and beta (1-->3)-linked glucose and alpha (1-->3)-linked galactose in natural glycoconjugates are recognized. Immunol Invest 2009; 38: 153-64.
99. Robyt JF, Yoon SH, Mukerjea R. Dextransucrase and the mechanism for dextran biosynthesis. Carbohydr Res 2008; 343: 3039-48.
100. Sverremark E, Fernandez C. Immunogenicity of bacterial carbohydrates: cholera toxin modulates the immune response against dextran B512. Immunology 1997, 92: 153-9.
101. Choi H, Choi SR, Zhou R, et al. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 2004; 11: 996-1004.
102. Ghosh D, Lee Y, Thomas S, et al. M13-templated magnetic nanoparticles for targeted in vivo imaging of prostate cancer. Nat Nanotechnol 2012; 7: 677-82.
103. Chen X, Lv H, Ye M, et al. Novel superparamagnetic iron oxide nanoparticles for tumor embolization application: preparation, characterization and double targeting. Int J Pharm 2012; 426: 248-55.
104. Sperling RA, Parak WJ. Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. Philos Transact A Math Phys Eng Sci 2010; 368: 1333-83.
105. Casals E, Pfaller T, Duschl A, et al. Time evolution of the nanoparticle protein corona. ACS Nano 2010; 4: 3623-32.
106. Monopoli MP, Walczyk D, Campbell A, et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011; 133: 2525-34.
107. Safi M, Courtois J, Seigneuret M, et al. The effects of aggregation and protein corona on the cellular internalization of iron oxide nanoparticles. Biomaterials 2011; 32: 9353-63.
108. He C, Hu Y, Yin L, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010; 31: 3657-66.
109. Swanson JA, Watts C. Macropinocytosis. Trends Cell Biol 1995, 5: 424-8.
110. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007; 2: 469-78.
111. Yang CY, Tai MF, Lin CP, et al. Mechanism of cellular uptake and impact of ferucarbotran on macrophage physiology. PLoS One 2011; 6: e25524.
112. Mercer J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol 2009; 11: 510-20.
113. Lunov O, Zablotskii V, Syrovets T, et al. Modeling receptormediated endocytosis of polymer-functionalized iron oxide nanoparticles by human macrophages. Biomaterials 2011; 32: 547-55.
114. Yu SS, Lau CM, Thomas SN, et al. Size-and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages. Int J Nanomedicine 2012; 7: 799-813.
115. Patel PC, Harrison RE. Membrane ruffles capture C3bi-opsonized particles in activated macrophages. Mol Biol Cell 2008; 19: 4628-39.
116. Moore A, Weissleder R, Bogdanov A, Jr. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 1997; 7: 1140-5.
117. von Zur Muhlen C, von Elverfeldt D, Bassler N, et al. Superparamagnetic iron oxide binding and uptake as imaged by magnetic resonance is mediated by the integrin receptor Mac-1 (CD11b/CD18): implications on imaging of atherosclerotic plaques. Atherosclerosis 2007; 193: 102-11.
118. Vidarsson G, van de Winkel JG. Fc receptor and complement receptor-mediated phagocytosis in host defence. Curr Opin Infect Dis 1998, 11: 271-8.
119. Gref R, Luck M, Quellec P, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000, 18: 301-13.
120. Wilhelm C, Billotey C, Roger J, et al. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 2003, 24: 1001-11.
121. Beduneau A, Ma Z, Grotepas CB, et al. Facilitated monocytemacrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One 2009; 4: e4343.
122. Peiser L, De Winther MP, Makepeace K, et al. The class A macrophage scavenger receptor is a major pattern recognition receptor for Neisseria meningitidis which is independent of lipopolysaccharide and not required for secretory responses. Infect Immun 2002, 70: 5346-54.
123. Raynal I, Prigent P, Peyramaure S, et al. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004; 39: 56-63.
124. Tu C, Ng TS, Sohi HK, et al. Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques. Biomaterials 2011; 32: 7209-16.
125. Chao Y, Karmali PP, Simberg D. Role of carbohydrate receptors in the macrophage uptake of dextran-coated iron oxide nanoparticles. Adv Exp Med Biol 2012; 733: 115-23.
126. Chao Y, Makale M, Karmali PP, et al. Recognition of Dextran-Superparamagnetic Iron Oxide Nanoparticle Conjugates (Feridex) via Macrophage Scavenger Receptor Charged Domains. Bioconjug Chem 2012 in press.
127. Veronese FM, Mero A, Caboi F, et al. Site-specific pegylation of G-CSF by reversible denaturation. Bioconjug Chem 2007; 18: 1824-30.
128. Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 1995; 16: 195-214.
129. Scott MD, Murad KL, Koumpouras F, et al. Chemical camouflage of antigenic determinants: stealth erythrocytes. Proc Natl Acad Sci USA 1997, 94: 7566-71.
130. Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008; 5: 505-15.
131. Shan X, Yuan Y, Liu C, et al. Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles. Biomed Microdevices 2009; 11: 1187-94.
132. Wang D, Kyluik DL, Murad KL, et al. Polymer-mediated immunocamouflage of red blood cells: effects of polymer size on antigenic and immunogenic recognition of allogeneic donor blood cells. Sci China Life Sci 2011; 54: 589-98.
133. Lartigue L, Wilhelm C, Servais J, et al. Nanomagnetic sensing of blood plasma protein interactions with iron oxide nanoparticles: impact on macrophage uptake. ACS Nano 2012; 6: 2665-78.
134. Wang FH, Kim DK, Yoshitake T, et al. Diffusion and clearance of superparamagnetic iron oxide nanoparticles infused into the rat striatum studied by MRI and histochemical techniques. Nanotechnology 2011; 22: 015103.
135. Hamad I, Hunter AC, Szebeni J, et al. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol 2008; 46: 225-32.
136. Kohler N, Fryxell GE, Zhang M. A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc 2004; 126: 7206-11.
137. Zhang C, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1. 5-T magnetic resonance scanner. Cancer Res 2007; 67: 1555-62.
138. Chen H, Wang L, Yeh J, et al. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. Biomaterials 2010; 31: 5397-407.
139. Fan C, Gao W, Chen Z, et al. Tumor selectivity of stealth multifunctionalized superparamagnetic iron oxide nanoparticles. Int J Pharm 2011; 404: 180-90.
140. Huang C, Neoh KG, Kang ET. Combined ATRP and 'click' chemistry for designing stable tumor-targeting superparamagnetic iron oxide nanoparticles. Langmuir 2012; 28: 563-71.
141. Wu EX, Tang H, Jensen JH. Applications of ultrasmall superparamagnetic iron oxide contrast agents in the MR study of animal models. NMR Biomed 2004; 17: 478-83.
142. Dobrovolskaia MA, Germolec DR, Weaver JL. Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol 2009; 4: 411-4.